kras mutation and glutathion glynac mutation: from undruggable to druggable in cancer Oncogenic Kras Maintains Pancreatic Tumors
Oncogenic Kras Maintains Pancreatic Tumors through Regulation of Anabolic Glucose Metabolism: Cell Targeting mutated GTPase KRAS in tumor therapies ScienceDirect What should we know about the 'undruggable' target KRAS? MedChemExpress Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines Metabolomics Springer Nature Link
Pay in 4 interest-free payments of $6.43 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



